Aldeyra Therapeutics, Inc. (ALDX)

Aldeyra Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	102.49	142.82	144.42	229.79	77.86	44.43
Short-Term Investments	30.55	0	29.88	0	0	28.94
Cash & Cash Equivalents	133.04	142.82	174.3	229.79	77.86	73.36
Cash Growth	-19.39%	-18.06%	-24.15%	195.14%	6.13%	-21.62%
Other Current Assets	7.81	4.99	6.72	2.96	5.2	1.8
Total Current Assets	140.85	147.81	181.02	232.75	83.06	75.17
Property, Plant & Equipment	0.46	0.52	0.27	0.38	0.29	0.35
Total Long-Term Assets	0.46	0.52	0.27	0.38	0.29	0.35
Total Assets	141.3	148.33	181.29	233.14	83.35	75.52
Accounts Payable	0.28	1.34	0.13	1.02	0.38	0.81
Deferred Revenue	6	6	0	0	0	0
Current Debt	15.45	15.39	1.16	0.23	3.89	0.23
Other Current Liabilities	-0.06	-0.46	14.07	10.52	8.13	11.87
Total Current Liabilities	21.68	22.26	15.36	11.77	12.41	12.91
Long-Term Debt	0.21	0.27	14.92	15.63	11.43	14.53
Other Long-Term Liabilities	6	6	0	0	0	0
Total Long-Term Liabilities	6.21	6.27	14.92	15.63	11.43	14.53
Total Liabilities	27.88	28.53	30.28	27.4	23.84	27.44
Total Debt	15.66	15.66	16.08	15.86	15.33	14.75
Debt Growth	-2.82%	-2.65%	1.42%	3.46%	3.88%	-
Retained Earnings	-402.34	-394.26	-356.72	-294.69	-236.92	-199.36
Comprehensive Income	-0	0	-0.1	0	0	0.01
Shareholders' Equity	113.42	119.8	151.01	205.74	59.51	48.08
Net Cash / Debt	117.38	127.17	158.22	213.93	62.53	58.61
Net Cash / Debt Growth	-21.18%	-19.63%	-26.04%	242.12%	6.69%	-37.38%
Net Cash Per Share	1.98	2.16	2.71	3.96	1.84	2.16
Working Capital	119.17	125.55	165.66	220.98	70.65	62.26
Book Value Per Share	1.91	2.03	2.58	3.81	1.75	1.77

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).